RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of carboplatin plus vincristine in treating children with retinoblastoma.
OBJECTIVES: I. Estimate the objective response rate in infants and children with retinoblastoma when treated with carboplatin (CBDCA) and vincristine (VCR) every 3 weeks for 24 weeks. II. Assess the success of this regimen in delaying radiotherapy and eliminating the need for surgery by estimating the cumulative incidence function of treatment failure. III. Estimate the cumulative incidence of failure of this regimen as measured by subsequent treatment with radiotherapy or surgery. OUTLINE: All patients receive carboplatin and vincristine every 3 weeks for a maximum of 8 courses. Patients with disease progression after at least 2 courses are removed from study and considered for alternative therapy. Patients are followed every 6 weeks for 1 year, every 2 months for 1 year, every 3-4 months for 3 years, and yearly for 12 years. PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study within 4.5 years.
Study Type
INTERVENTIONAL
Purpose
TREATMENT
Enrollment
25
University of Tennessee, Memphis Cancer Center
Memphis, Tennessee, United States
Saint Jude Children's Research Hospital
Memphis, Tennessee, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.